Provided by Tiger Fintech (Singapore) Pte. Ltd.

DOGWOOD THERAPEUTICS INC

5.36
-0.1200-2.19%
Post-market: 5.360.00000.00%19:50 EDT
Volume:116.40K
Turnover:627.92K
Market Cap:10.24M
PE:-0.43
High:5.55
Open:5.50
Low:5.20
Close:5.48
Loading ...

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Newsfile
·
Yesterday

HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral

MT Newswires Live
·
23 Apr

Dogwood Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
23 Apr

Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings

Benzinga
·
21 Apr

BRIEF-Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance

Reuters
·
11 Apr

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

THOMSON REUTERS
·
11 Apr

DWTX: Interim Data for Phase 2b Trial in 4Q25…

Zacks Small Cap Research
·
04 Apr

BRIEF-Dogwood Therapeutics Regains Nasdaq Compliance

Reuters
·
03 Apr

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

THOMSON REUTERS
·
03 Apr

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

GlobeNewswire
·
03 Apr

Press Release: Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
01 Apr

Ten option delistings on March 24th

TIPRANKS
·
24 Mar

Dogwood Therapeutics: Announces Dosing of First Patient in Phase 2B Trial Evaluating Halneuron in Patients With Chemotherapy-Induced Neuropathic Pain

THOMSON REUTERS
·
18 Mar

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

GlobeNewswire
·
18 Mar

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…

Zacks Small Cap Research
·
18 Mar

Sector Update: Health Care Stocks Softer Thursday Afternoon

MT Newswires Live
·
14 Mar

Maxim Group Remains a Buy on Dogwood Therapeutics (DWTX)

TIPRANKS
·
14 Mar

Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge

MT Newswires Live
·
13 Mar

Dogwood Therapeutics Inc: Proceeds From Financing, When Added to Existing Cash, Fund Operations Through Q1 2026

THOMSON REUTERS
·
13 Mar

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
13 Mar